Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has announced that the president and CEO Jim Tobin will be extending his tenure at the company. The company said Mr Tobin plans to remain in his role for the foreseeable future.
Subscribe to our email newsletter
The company has also announced that Fred Colen will become the president of its Cardiac Rhythm Management (CRM) group, and that Paul LaViolette, COO, will be retiring from the company.
Mr Colen has been with the company since 1999 in a number of leadership positions. Most recently, Mr Colen has served as executive vice president of operations and technology at CRM. Prior to this role, Mr Colen served as executive vice president and chief technology officer for the company.
Mr LaViolette first joined the company in 1994, and he has also served in a number of leadership positions. Mr LaViolette has been COO since 2005.
Pete Nicholas, co-founder and chairman of the board at Boston Scientific, said: I am very pleased to announce that Jim Tobin will be extending his tenure as president and CEO of Boston Scientific. Two years ago we announced a similar extension. The time is now right for Jim to turn his full attention and energies back to the core challenges facing the company as a whole, especially those relating to strategy, the development of our human capital, organizational efficiency and effectiveness, and simplifying and streamlining operations.